Age-related macular degeneration (AMD) is the most common macular disease in Australia and is responsible for half of all blindness and severe vision loss. However, there are now exciting therapeutic treatments for dry AMD on the horizon.
To help identify patients at risk of progressing to vision-threatening late AMD, clinicians must adopt comprehensive multi-modal techniques.
The Zeiss Cirrus optical coherence tomographer (OCT) enables clinicians to closely monitor qualitative and quantitative changes in the retinal pigment epithelium layer (RPE), including elevations, atrophic areas, and proximity to fovea.
Using advanced RPE analysis, clinicians are well equipped to accurately grade the disease and determine referral and future treatment decisions for patients living with geographic atrophy (GA).
Forum Retina Workplace provides longitudinal insights for progression analysis, adding further value by plotting all historical RPE measurements. Fundus imaging overlays assist in patient education and help guide future treatments for one of the biggest unmet needs in ophthalmology today.
Contact: Zeiss Surgical Account Manager
